
RLS Therapeutics develops novel small molecule treatments for various diseases.
Founded with a mission to innovate in the pharmaceutical landscape, RLS Therapeutics focuses on developing novel small molecule therapeutics to address a wide range of diseases. The company leverages its proprietary technology, RPRx (Recycling Polycarbonyl Redox Therapy), which targets health disorders linked to impaired mitochondrial function. By prioritizing the reduction of risk in drug development, RLS Therapeutics aims to bring effective treatments to market more efficiently.
Notable figures associated with RLS Therapeutics include leading scientists and industry experts who contribute to its pioneering research and development efforts. The company has garnered attention for its innovative approach and potential impact on treating mitochondrial-related disorders. Through its commitment to advancing medical science, RLS Therapeutics is poised to make significant contributions to the healthcare industry, improving patient outcomes and setting new standards in therapeutic development.

Rediscovery Life Sciences
rediscoveryls.com

RS BioTherapeutics

Rubix LS
rubixls.com

Relay Therapeutics
relaytx.com

Lysosomal Therapeutics
lysosomaltx.com

Resilience Therapeutics

Asha Therapeutics

Lucy Therapeutics

Receptor Life Sciences
receptorlife.com

Rjs Biologics

Exalys Therapeutics

Mitochon Pharmaceuticals
mitochonpharma.com

Pretzel Therapeutics
pretzeltx.com

Remix Therapeutics

Retro Biosciences
retro.bio
Companies similar to RLS Therapeutics include Rediscovery Life Sciences, RS BioTherapeutics, Rubix LS and Relay Therapeutics.
RLS Therapeutics was founded in 2016.
RLS Therapeutics' headquarters is located in Nashville, TN, US.
RLS Therapeutics' most recent funding round was for $635k (USD) in November 2019.
As of Nov 1, 2019, RLS Therapeutics has raised a total of $1.4M (USD).
RLS Therapeutics has 7 employees as of Feb 4, 2024.